

Application No.: 09/657,336

2

Docket No.: 500862001500

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): A modified anti-viral peptide comprising ~~a peptide having been modified to contain a maleimide containing group which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, wherein~~ said peptide comprising comprises an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group, wherein the ratio of peptide to serum albumin is 1:1.

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (Currently amended) The modified peptide of claim 1 wherein said ~~peptide is DP 107 and comprises the amino acid sequence~~ [[of]] is SEQ ID NO:2.

Claim 5 (canceled)

Claim 6 (Currently amended): The modified peptide of claim 1 wherein said ~~peptide~~ amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

Claim 19 (Currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically

sf-2050052

BEST AVAILABLE COPY

Application No.: 09/657,336

3

Docket No.: 500862001500

acceptable medium, a modified peptide ~~including a peptide having been modified to contain a~~
~~comprising a maleimide containing group which is reactive with cysteine 34 of serum albumin to~~
~~form a stable covalent bond, wherein~~ said peptide comprises an amino acid sequence wherein said
sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148,
SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID
NO:543, SEQ ID NO:544, and SEQ ID NO:545, ~~wherein said sequence exhibiting~~ exhibits an anti-
viral activity against human immunodeficiency virus (HIV) ~~wherein and~~ said peptide is covalently
bonded to cysteine 34 of ~~serum~~ albumin through said maleimide containing group, wherein the ratio
of peptide to ~~serum~~ albumin is 1:1.

Claim 20 (canceled)

Claim 21 (Currently amended): The composition of claim ~~20~~ 19 wherein said ~~peptide is DP~~
~~107 comprising the~~ amino acid sequence ~~[[of]]~~ is SEQ ID NO:2.

Claims 22-30 (canceled)

Claim 31 (Currently amended): The composition of claim 19 wherein said ~~peptide~~
~~comprises an~~ amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ
ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID
NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 32-35 (canceled)

Claim 36 (Previously presented): A composition comprising the modified anti-viral peptide
of claim 1 in a physiologically acceptable medium.

Claim 37 (canceled)

Claim 38 (Currently amended): The composition of claim 36 wherein said ~~modified anti-~~
~~viral peptide comprises the~~ amino acid sequence ~~[[of]]~~ is SEQ ID NO:2.

sf-2050052

BEST AVAILABLE COPY

Application No.: 09/657,336

4

Docket No.: 500862001500

Claim 39 (Currently amended): The composition of claim 36 wherein said ~~modified anti-viral peptide comprises an~~ amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claim 40-55 (canceled)

Please add the following new claims:

Claim 56 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:147.

Claim 57 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:148.

Claim 58 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:149.

Claim 59 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:179.

Claim 60 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:180.

Claim 61 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:181.

Claim 62 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:542.

Claim 63 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:543.

sf-2050052

BEST AVAILABLE COPY

Application No.: 09/657,336

5

Docket No.: 500862001500

Claim 64 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:544.

Claim 65 (new): The modified anti-viral peptide of claim 1 wherein said amino acid sequence is SEQ ID NO:545.

Claim 66 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:147.

Claim 67 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:148.

Claim 68 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:149.

Claim 69 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:179.

Claim 70 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:180.

Claim 71 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:181.

Claim 72 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:542.

Claim 73 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:543.

Claim 74 (new): The composition of claim 19 wherein said modified amino acid sequence is SEQ ID NO:544.

sf-2050052

BEST AVAILABLE COPY

Application No.: 09/657,336

6

Docket No.: 500862001500

Claim 75 (new): The composition of claim 19 wherein said modified amino acid sequence is
SEQ ID NO:545.

BEST AVAILABLE COPY

sf-2050052